Canadian biotech Aptose Biosciences (APTO)
has a lot of work ahead of it, as the company’s two lead drugs haven’t
even completed Phase I testing yet. Even so, the preclinical efficacy
and safety data on APTO-253 and CG’806 have looked quite encouraging,
and I believe this is a highly speculative opportunity that continues to
offer interesting upside. Now with the announcement that the FDA has
lifted the clinical hold on APTO-253, Aptose is back on track to have at
least one, and possibly two, promising compounds in the clinic before
the end of 2018.
Continue here:
Aptose Biosciences Back On Track In The Clinic
No comments:
Post a Comment